ArticleFrontiers in cell and developmental biology2025
Melatonin and agomelatine alleviate ivermectin-induced mouse spermatogonia apoptosis via suppression of oxidative stress and calcium overload.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug toxicity poses a significant threat to male fertility, and its mechanism is often associated with redox imbalance and mitochondrial dysfunction. Ivermectin (IVM), an anthelmintic increasingly explored for new therapeutic applications, induces apoptosis and impairs proliferation in spermatogonia via mitochondria-associated cellular injury at high concentrations in vitro. This study evaluated the protective effects of melatonin, agomelatine, and pinoline, as mitochondria-directed cytoprotectants. Methods: Cultured type B spermatogonia were pretreated with 1 μM melatonin, agomelatine, or pinoline for 24 h under low-serum conditions, followed by exposure to 16 μM IVM. Cell proliferation was assessed by cell counting and Ki67 immunocytochemistry. Mechanistic analyses included fluorescence imaging of reactive oxygen species (ROS) using 2',7'-dichlorodihydrofluorescein diacetate, cytosolic Ca Results: Unlike pinoline, melatonin and agomelatine effectively suppressed IVM-induced oxidative stress and Ca Conclusion: Melatonin and agomelatine protect the male reproductive system from drug-induced toxicity by restoring redox homeostasis and mitochondrial function. These findings provide mechanistic insight into melatonin-based therapeutic strategies and the development of fertility preserving agents targeting mitochondria-mediated cellular injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.